Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This book summarizes the progress made across the international medical and scientific research communities towards the goal of converting a chronic autoimmune disease into a drug-free reversible illness using hematopoietic stem cell transplantation (HSCT) and other cellular therapies to generate sustained immune tolerance.
This book summarizes the progress made across the international medical and scientific research communities towards the goal of converting a chronic autoimmune disease into a drug-free reversible illness using hematopoietic stem cell transplantation (HSCT) and other cellular therapies to generate sustained immune tolerance.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
Richard K. Burt, MD (www.astemcelljourney.com) is Fulbright Scholar and Professor of Medicine at Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, and the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR). Dominique Farge, MD, PhD is Professor of Internal Medicine at Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, (AP-HP), University of Paris, Paris, France; Adjunct Professor at McGill University, Montreal, Canada; and Chairperson of the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party from 2010 to 2016. Milton A. Ruiz, MD, PhD is former Professor at the University of São Paulo and the head coordinator of the Hematopoietic Stem Cell Transplant Service of the Beneficência Portuguesa Hospital of São José do Rio Preto, São Paulo, Brazil. Riccardo Saccardi, MD is Director of Cellular Therapies and Transfusion Medicine Department at Careggi University Hospital in Florence, Italy and Chairperson of the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party from 2004 to 2010. John A. Snowden, MD is Consultant Haematologist & Director of Blood and Marrow Transplantation, Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Honorary Professor, Department of Oncology & Metabolism, The University of Sheffield, Sheffield, UK; Honorary Clinical Professor, The Cancer Institute, Department of Haematology, University College London, UK; and Chairperson of the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party from 2016 to 2020.
Inhaltsangabe
Table of Contents Section 1- Biology of Immune Cells Ch 1 B cells in aging, age-associated diseases and stem cell transplantation Ch 2 T cell biology: changes with disease, aging, and hematopoietic stem cell transplantation Ch 3 Plasma cells in autoimmunity Ch 4 CAR T cells for Autoimmunity Ch 5 Regulatory T cells for the treatment of autoimmune diseases Ch 6 Mesenchymal Stromal Cells Derived Extracellular Vesicles Section 2 - Biology of Stem Cells Ch 7 Induced Pluripotent Stem Cells: the story of genetic reprogramming Ch 8 Mesenchymal stromal cell biology and clinical application Ch 9 Neural Stem Cell Biology Ch 10 Hematopoietic stem cells: Hierarchical versus Continuum Ch 11 Biology of Umbilical Cord Blood Cells Section 3 - Regulatory requirements Ch 12 Quality, Accreditation, and Regulation in HSCT and Cellular Therapy for Autoimmune Diseases Ch 13 EUROPEAN PERSPECTIVE ON CELLULAR THERAPY: GOOD TISSUE PRACTICE (GTP) VERSUS GOOD MANUFACTURING PRACTICE (GMP). Ch 14 GMP Facility Requirements in the United States of America Section 4 - Mesenchymal Stem Cells for Immune Diseases Ch 15 Mesenchymal stromal cell therapy for acute graft versus host disease - from bench to clinical approval Ch 16 Adipose-Derived Stem Cells for Systemic Sclerosis Digital Ulcers Ch 17 Musculoskeletal stromal/progenitor cells-based cell therapy for Rheumatoid Arthritis (RA) Ch 18 Mesenchymal Stromal cells for Systemic Sclerosis Ch 19 Mesenchymal stem cells (MSC) for systemic lupus erythematosus (SLE) Ch 20 Mesenchymal stem/stromal cells for multiple sclerosis and other neurological diseases Ch 21 Mesenchymal stromal cells for perianal fistulizing crohn's disease Ch 22 Umbilical Cord Blood or Mesenchymal Stromal Cells as Potential Therapies for Autism Spectrum Disorder Section 5 - General concepts: HSCT for Autoimmune Diseases Ch 23 Animal models of bone marrow transplantation for autoimmune diseases Ch 24 Autologous HSCT conditioning regimens for autoimmune diseases Ch 25 Immune reconstitution after hematopoietic stem cell transplantation in autoimmune disease Ch 26 Microbiota and immune response Ch 27 Infectious complications in patients undergoing HSCT for autoimmune diseases. Ch 28 Early Toxicity and Supportive Care of HSCT for Autoimmune Diseases Ch 29 Late toxicity and supportive care of patients undergoing haematopoietic cell transplantation for autoimmune diseases Ch 30 Transfusion Medicine Ch 31 International Registries Sites / Indications / Activity for HSCT in Autoimmune Diseases: the European Society for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) Ch 32 Hematopoietic stem cell mobilization, collection, apheresis, and harvest procedures Section 6 - Allogeneic HSCT for Autoimmune disease Ch 33 Hematopoietic Stem Cell Donor Registries: Search Strategies and HLA Methodologies Ch 34 Allogeneic HSCT and Graft-versus-Host Disease (GvHD): general principles with reference to autoimmune diseases Ch 35 Haematopoietic cell transplantation in monogenic autoimmune diseases Ch 36 Advances In The Pathogenesis And Treatment Of Immune Mediated Aplastic Anemia Section 7- HSCT for autoimmune disease Multiple Sclerosis Ch 37 Magnetic Resonance Imaging in Multiple Sclerosis Ch 38 Multiple Sclerosis Ch 39 Disease-modifying therapies and supportive care of multiple sclerosis Ch 40 Autologous hematopoietic stem cell transplantation for Secondary Progressive Multiple Sclerosis Ch 41 Autologous hematopoietic stem cell transplantation for Relapsing Remitting Multiple Sclerosis Ch 42 Immune mechanisms of autologous hematopoietic stem cell transplantation for multiple sclerosis Chronic Inflammatory Demyelinating Polyradiculoneuropathy Ch 43 Basics and interpretation of electrodiagnostic testing Ch 44 Diagnosis and Differentiation of CIDP from other peripheral polyneuropathies Ch 45 Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy Neuromyelitis Optica Ch 46 Autologous and Allogeneic HSCT for AQP4-IgG positive Neuromyelitis Optica Spectrum Disorders Systemic Sclerosis Ch 47 Systemic Sclerosis Ch 48 The Systemic Sclerosis Heart Ch 49 Scleroderma Renal Crisis with special considerations for Autologous Hematopoietic Stem Cell Transplant Ch 50 Systemic Sclerosis and the Lung Ch 51 AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SYSTEMIC SCLEROSIS Crohn Disease Ch 52 Crohn's Disease: Incidence, Diagnosis, Standard Treatment, Prognosis, Outcome Measures Ch 53 Hematopoietic Stem cell transplantation an alternative to treat Crohn's disease Type I Diabetes Mellitus Ch 54 Hematopoietic Stem Cell Transplantation for Type I Diabetes Mellitus Systemic Lupus Erythematosus Ch 55 Hematopoietic stem cell transplantation for systemic lupus erythematosus (SLE) Celiac Disease Ch 56 Hematopoietic Stem Cell Transplantation for Refractory Celiac Disease type II Section 8 - Developing indications for HSCT Ch 57 Haematopoietic stem cell transplantation for Juvenile Idiopathic Arthritis Ch 58 Haematopoietic Stem Cell Transplantation for Rheumatoid Arthritis Ch 59 Hematopoietic Stem Cell Transplantation for Behçet's Syndrome Ch 60 Hematopoietic Stem Cell Transplantation and Myasthenia Gravis Ch 61 Autologous Haematopoietic Stem Cell Transplantation in Stiff Person Spectrum Disorder Ch 62 Hematopoietic Stem Cell Transplant-Based Treatment for Psychiatric Disorders Ch 63 Hematopoietic Stem Cell Transplantation for Psoriasis and Pemphigus Vulgaris Section 9 - Ethics and economics Ch 64 Health Economics of Multiple Sclerosis Ch 65 Ethics of Stem Cells and Stem Cell Transplantation for Autoimmune diseases Ch 66 Is Healthcare a Human Right? Ch 67 Appendices
Table of Contents Section 1- Biology of Immune Cells Ch 1 B cells in aging, age-associated diseases and stem cell transplantation Ch 2 T cell biology: changes with disease, aging, and hematopoietic stem cell transplantation Ch 3 Plasma cells in autoimmunity Ch 4 CAR T cells for Autoimmunity Ch 5 Regulatory T cells for the treatment of autoimmune diseases Ch 6 Mesenchymal Stromal Cells Derived Extracellular Vesicles Section 2 - Biology of Stem Cells Ch 7 Induced Pluripotent Stem Cells: the story of genetic reprogramming Ch 8 Mesenchymal stromal cell biology and clinical application Ch 9 Neural Stem Cell Biology Ch 10 Hematopoietic stem cells: Hierarchical versus Continuum Ch 11 Biology of Umbilical Cord Blood Cells Section 3 - Regulatory requirements Ch 12 Quality, Accreditation, and Regulation in HSCT and Cellular Therapy for Autoimmune Diseases Ch 13 EUROPEAN PERSPECTIVE ON CELLULAR THERAPY: GOOD TISSUE PRACTICE (GTP) VERSUS GOOD MANUFACTURING PRACTICE (GMP). Ch 14 GMP Facility Requirements in the United States of America Section 4 - Mesenchymal Stem Cells for Immune Diseases Ch 15 Mesenchymal stromal cell therapy for acute graft versus host disease - from bench to clinical approval Ch 16 Adipose-Derived Stem Cells for Systemic Sclerosis Digital Ulcers Ch 17 Musculoskeletal stromal/progenitor cells-based cell therapy for Rheumatoid Arthritis (RA) Ch 18 Mesenchymal Stromal cells for Systemic Sclerosis Ch 19 Mesenchymal stem cells (MSC) for systemic lupus erythematosus (SLE) Ch 20 Mesenchymal stem/stromal cells for multiple sclerosis and other neurological diseases Ch 21 Mesenchymal stromal cells for perianal fistulizing crohn's disease Ch 22 Umbilical Cord Blood or Mesenchymal Stromal Cells as Potential Therapies for Autism Spectrum Disorder Section 5 - General concepts: HSCT for Autoimmune Diseases Ch 23 Animal models of bone marrow transplantation for autoimmune diseases Ch 24 Autologous HSCT conditioning regimens for autoimmune diseases Ch 25 Immune reconstitution after hematopoietic stem cell transplantation in autoimmune disease Ch 26 Microbiota and immune response Ch 27 Infectious complications in patients undergoing HSCT for autoimmune diseases. Ch 28 Early Toxicity and Supportive Care of HSCT for Autoimmune Diseases Ch 29 Late toxicity and supportive care of patients undergoing haematopoietic cell transplantation for autoimmune diseases Ch 30 Transfusion Medicine Ch 31 International Registries Sites / Indications / Activity for HSCT in Autoimmune Diseases: the European Society for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) Ch 32 Hematopoietic stem cell mobilization, collection, apheresis, and harvest procedures Section 6 - Allogeneic HSCT for Autoimmune disease Ch 33 Hematopoietic Stem Cell Donor Registries: Search Strategies and HLA Methodologies Ch 34 Allogeneic HSCT and Graft-versus-Host Disease (GvHD): general principles with reference to autoimmune diseases Ch 35 Haematopoietic cell transplantation in monogenic autoimmune diseases Ch 36 Advances In The Pathogenesis And Treatment Of Immune Mediated Aplastic Anemia Section 7- HSCT for autoimmune disease Multiple Sclerosis Ch 37 Magnetic Resonance Imaging in Multiple Sclerosis Ch 38 Multiple Sclerosis Ch 39 Disease-modifying therapies and supportive care of multiple sclerosis Ch 40 Autologous hematopoietic stem cell transplantation for Secondary Progressive Multiple Sclerosis Ch 41 Autologous hematopoietic stem cell transplantation for Relapsing Remitting Multiple Sclerosis Ch 42 Immune mechanisms of autologous hematopoietic stem cell transplantation for multiple sclerosis Chronic Inflammatory Demyelinating Polyradiculoneuropathy Ch 43 Basics and interpretation of electrodiagnostic testing Ch 44 Diagnosis and Differentiation of CIDP from other peripheral polyneuropathies Ch 45 Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy Neuromyelitis Optica Ch 46 Autologous and Allogeneic HSCT for AQP4-IgG positive Neuromyelitis Optica Spectrum Disorders Systemic Sclerosis Ch 47 Systemic Sclerosis Ch 48 The Systemic Sclerosis Heart Ch 49 Scleroderma Renal Crisis with special considerations for Autologous Hematopoietic Stem Cell Transplant Ch 50 Systemic Sclerosis and the Lung Ch 51 AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SYSTEMIC SCLEROSIS Crohn Disease Ch 52 Crohn's Disease: Incidence, Diagnosis, Standard Treatment, Prognosis, Outcome Measures Ch 53 Hematopoietic Stem cell transplantation an alternative to treat Crohn's disease Type I Diabetes Mellitus Ch 54 Hematopoietic Stem Cell Transplantation for Type I Diabetes Mellitus Systemic Lupus Erythematosus Ch 55 Hematopoietic stem cell transplantation for systemic lupus erythematosus (SLE) Celiac Disease Ch 56 Hematopoietic Stem Cell Transplantation for Refractory Celiac Disease type II Section 8 - Developing indications for HSCT Ch 57 Haematopoietic stem cell transplantation for Juvenile Idiopathic Arthritis Ch 58 Haematopoietic Stem Cell Transplantation for Rheumatoid Arthritis Ch 59 Hematopoietic Stem Cell Transplantation for Behçet's Syndrome Ch 60 Hematopoietic Stem Cell Transplantation and Myasthenia Gravis Ch 61 Autologous Haematopoietic Stem Cell Transplantation in Stiff Person Spectrum Disorder Ch 62 Hematopoietic Stem Cell Transplant-Based Treatment for Psychiatric Disorders Ch 63 Hematopoietic Stem Cell Transplantation for Psoriasis and Pemphigus Vulgaris Section 9 - Ethics and economics Ch 64 Health Economics of Multiple Sclerosis Ch 65 Ethics of Stem Cells and Stem Cell Transplantation for Autoimmune diseases Ch 66 Is Healthcare a Human Right? Ch 67 Appendices
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
